Clinical trial
Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or…
NCT00054405 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00054405 |
|---|---|
| Title | Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma |
| Official title | A Phase I Investigation of IL-12 (NSC 672423)/Pulse IL-2 (Aldesleukin) in Children With Persistent and/or Refractory Neuroblastoma (13623) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent Neuroblastoma |
| Intervention type | Biological |
| Interventions | recombinant interleukin-12, aldesleukin |
| Enrollment | 40 |
| Start date | Dec 1, 2002 |
| Primary completion | May 1, 2009 |
| First posted | Feb 6, 2003 |
| Last update posted | Apr 9, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: